Equities research analysts forecast that Immune Design Corp (NASDAQ:IMDZ) will report sales of $810,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immune Design’s earnings, with estimates ranging from $400,000.00 to $1.22 million. Immune Design posted sales of $2.06 million during the same quarter last year, which suggests a negative year over year growth rate of 60.7%. The company is scheduled to announce its next quarterly earnings report on Tuesday, March 6th.
On average, analysts expect that Immune Design will report full year sales of $810,000.00 for the current fiscal year, with estimates ranging from $7.10 million to $9.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $16.37 million per share, with estimates ranging from $14.73 million to $18.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Immune Design.
Immune Design (NASDAQ:IMDZ) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%.
Shares of Immune Design (IMDZ) opened at $3.70 on Monday. The stock has a market cap of $177.81, a P/E ratio of -1.74 and a beta of 2.36. Immune Design has a fifty-two week low of $3.50 and a fifty-two week high of $13.05.
In other news, Director Peter Svennilson acquired 2,681,000 shares of Immune Design stock in a transaction dated Friday, October 27th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Carlos V. Paya sold 7,970 shares of the firm’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $4.17, for a total transaction of $33,234.90. Following the completion of the sale, the chief executive officer now owns 114,560 shares in the company, valued at $477,715.20. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 5,300,000 shares of company stock worth $21,795,000 and sold 13,959 shares worth $58,209. 20.70% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bain Capital Public Equity Management LLC grew its position in shares of Immune Design by 393.1% in the 2nd quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock valued at $3,797,000 after buying an additional 310,433 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Immune Design by 118.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after buying an additional 288,009 shares during the last quarter. Sectoral Asset Management Inc purchased a new position in shares of Immune Design in the 2nd quarter valued at $1,641,000. Numeric Investors LLC purchased a new position in shares of Immune Design in the 2nd quarter valued at $1,641,000. Finally, Vanguard Group Inc. grew its position in shares of Immune Design by 37.9% in the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock valued at $5,118,000 after buying an additional 144,408 shares during the last quarter. Institutional investors and hedge funds own 29.34% of the company’s stock.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.